Featured

The surprising effect of TOX in CD4+ T cells

In settings of chronic antigen stimulation, such as chronic infection and cancer, expression of the transcription factor TOX in CD8+ T cells has been associated with cell persistence and survival, but also with exhaustion, dysfunction, and poor prog...

Dynamic reprogramming of the tumor immune network via multicycle checkpoint degradation for cancer immunotherapy

Chi et al. engineered a recyclable PD-L1 degrader (RECYC) by fusing a moderate-affinity peptide binder of PD-L1 to an aptamer against the ubiquitous endolysosomal trafficking receptor CI-M6PR. RECYC r...

Engineering CAR T cells to secrete VEGF-neutralizing scFvs enhances antitumor activity against solid tumors

To improve anti-angiogenic therapies in VEGF-overexpressing solid tumors, Gao et al. engineered CAR T cells to secrete anti-VEGF scFvs (CAR-αVEGF T cells) and compared their efficacy with standard CAR...

Modulating AP-1 enables CAR T cells to establish an intratumoral stemlike reservoir and overcomes resistance to PD-1 blockade

ROR1 CAR T cells infiltrated ROR1+ NSCLC mouse tumors, but lost TCF1 expression and failed to maintain a progenitor exhausted (Tpex) population. The addition of anti-PD-L1 did not improve CAR T cell c...

Nous-209 neoantigen vaccine for cancer prevention in Lynch syndrome carriers: a phase 1b/2 trial

D’Alise and Willis et al. presented results from a phase 1b/2 single-arm trial of 45 Lynch syndrome (LS) carriers treated with Nous-209 – an IM, heterologous, prime/boost, virus-based vaccine encoding...

See all for this week

Previous Digests

Neoantigen vaccination boosts long-lasting T cell responses in TNBC

March 11, 2026

Triple-negative breast cancer (TNBC) is characterized by DNA repair deficiency, genomic instability, and an immunogenic tumor microenvironment, suggesting it might serve as a candidate for individualized vaccination targeting somatic tumor mutation-associated neoantigens. Sahin, Schmidt, et al. recently published the...

AACR IO 2026

March 4, 2026

The ACIR team attended the AACR IO meeting held on February 18-21, 2026 in Los Angeles, CA, USA. This week’s extensive special feature covers select talks from the conference. We have organized the content by topics below. T cellsPhilip...

Flt3L fuels DCs to promote ICB-responsive Tpex cells

February 25, 2026

An important predictor of response to immune checkpoint blockade (ICB) is the presence of precursor exhausted T cells (Tpex) in the tumor. Conventional type 1 DCs (cDC1) are known to maintain these Tpex, and modulation of these factors might...

See More Digests

Watch ACIR in action

In November 2019, ACIR received the Visionary Award from the Cambridge Chamber of Commerce.

Watch the 3-minute video explaining ACIR's mission and goal:

In September 2020, ACIR was featured in the documentary The American Dream on Bloomberg TV.

Watch the 6-minute segment on the story behind your favorite digest here:

Donate to support researchers

About ACIR

ACIR's mission is to fast-track cancer immunotherapy research by helping researchers stay on top of the new literature in this fast-moving and multifaceted field, fostering their creativity and productivity in bringing us ever closer to curing this deadly disease.

Ute Burkhardt

Ed Fritsch

Lauren Hitchings

Gaëlle Llambi

Maartje Wouters

Alex Najibi

Katherine J. Turner

Stan Wolf

Paula Hochman

Shishir Pant

Nathan Suek

Morgan Janes

More About Us

TESTIMONIALS

I'm a big fan of ACIR. I enjoy their weekly newsletters with clear, concise, and insightful summaries, complemented by excellent images. I've even used the images in some of my presentations to explain complex cancer immunotherapy findings. In our rapidly evolving field, their reliable and well-curated updates are invaluable.

— Carl H. June, MD

Richard W. Vague Professor in Immunotherapy; Professor of PL&M; Director, Center for Cellular Immunotherapies; Director, Parker Institute for Cancer Immunotherapy; University of Pennsylvania Perelman School of Medicine. (Supporter since 2025).

Testimonials